Neurocrine Biosciences Inc (NB3 F) stock market data APIs
€112.3105
0(0%)
as of January 19, 2026
Try our APIs with
free plan!
Neurocrine Biosciences Inc Financial Data Overview
Price chart is built with
Anychart
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Prev. Close
112.3105
Open
112.3105
High
112.3105
Low
112.3105
52 wk Range
77.78-147.45
Market Cap
11 370 M
P/E Ratio
31.2604
Shares Outstanding
99 706 K
Revenue
2 683 M
EPS
0.8757
Beta
0.284
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Neurocrine Biosciences Inc data using free add-ons & libraries
Get Neurocrine Biosciences Inc Fundamental Data
Neurocrine Biosciences Inc Fundamental data includes:
- Net Revenue: 2 683 M
- EBITDA: 570 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2023-08-01
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Neurocrine Biosciences Inc News
New
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR
INGREZZA showed a nearly two-fold higher VMAT2 occupancy, consistent with greater potency when compared to AUSTEDO XR (deutetrabenazine) after a single dose of each treatment VMAT2 occupancy is a key ...
Reassessing Neurocrine Biosciences (NBIX) After Recent Share Price Weakness
If you are wondering whether Neurocrine Biosciences is fairly priced or offering value right now, you are not alone. This article is designed to help you size that up quickly. The stock recently close...
How Eli Lilly's Plan To Buy Ventyx For $1.2 Billion Could Benefit Neumora, Neurocrine
Eli Lilly's plan to buy Ventyx for $1.2 billion benefits more than the takeover target, an analyst said Thursday. Continue Reading
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. Pacific Time on Monday, January 12, 2...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
